FEBS Lett 459:205C210. This variant, called the RGDA/Q112D disease, consists of multiple mutations in CA: H87R, A88G, P90D, P93A, and Q112D. To investigate how an EACC IFN-hypersensitive disease can develop to conquer IFN–mediated blocks focusing on the viral capsid, we adapted the RGDA/Q112D disease in IFN–treated cells. We successfully isolated IFN–resistant viruses which contained either a solitary Q4R substitution or the double amino acid switch G94D/G116R. These two IFN- resistance mutations variably changed the level of sensitivity of CA binding to human being myxovirus resistance B (MxB), cleavage and polyadenylation specificity element 6 (CPSF6), and cyclophilin A (CypA), indicating that the observed loss of level of sensitivity was not due to relationships with these known sponsor CA-interacting factors. In contrast, the two mutations apparently functioned through unique mechanisms. The Q4R mutation dramatically accelerated the kinetics of reverse transcription and initiation of uncoating of the RGDA/Q112D disease in the presence or absence of IFN-, whereas the G94D/G116R mutations affected reverse transcription only in the presence of IFN-, most consistent with a mechanism of the disruption of binding to an unfamiliar IFN–regulated host element. These results suggest that HIV-1 can exploit multiple, known sponsor factor-independent pathways to avoid IFN–mediated restriction by altering capsid sequences and subsequent biological properties. IMPORTANCE HIV-1 illness causes powerful innate immune activation in virus-infected individuals. This immune activation is definitely characterized by elevated levels of type I interferons (IFNs), which can block HIV-1 replication. Recent studies suggest that the viral capsid protein (CA) is definitely a determinant for the level of sensitivity of HIV-1 to IFN-mediated restriction. Specifically, it was reported that the loss of CA relationships with CPSF6 or CypA prospects to higher IFN level EACC of sensitivity. However, the molecular mechanism of CA adaptation to IFN level of sensitivity is largely unfamiliar. Here, we experimentally developed an IFN–hypersensitive CA mutant which showed decreased binding to CPSF6 and CypA in IFN–treated cells. The CA mutations that emerged from this adaptation indeed conferred IFN- resistance. Our genetic assays suggest a limited contribution of known sponsor factors to IFN- resistance. Strikingly, one of these mutations accelerated the kinetics of reverse transcription and SLC12A2 uncoating. Our findings suggest that HIV-1 selected multiple, known sponsor factor-independent pathways to avoid IFN–mediated restriction. protein binding between CA and a CPSF6 peptide (26, 50,C53). We used an SeV vector to express HA-tagged CPSF6-358 in MT4 cells (Fig. 6B). Cells infected with an SeV-expressing CPSF6-358-FG321/322AA mutant, in addition to mock-infected cells, served as negative settings. Infection of the WT disease was highly restricted in CPSF6-358-expressing cells compared to that in CPSF6-358-FG321/322AA-expressing or SeV? cells (Fig. 7A). In contrast, infection of the N74D disease was not affected by CPSF6-358 (Fig. 7A and ?andB).B). These findings validate those of our experimental assay. We found that, like its WT counterpart, the RGDA/Q112D disease was clogged by CPSF6-358. However, the relative infectivity of the RGDA/Q112D disease in CPSF6-358-expressing cells was not as low as that of the WT disease. Even though difference was rather small (20.1% versus 8.1% for the RGDA/Q112D disease and the WT disease, respectively), the difference was statistically significant (ideals were determined by the Kruskal-Wallis test followed by Dunns multiple assessment. ****, gene were used in the present study. We also used pBru3oriEnv-luc2 (70, 71) and pBru3oriEnv-NanoLuc plasmids, in which the BssHII/ApaI fragments were replaced with the related fragment of pNL4-3 plasmids. To generate replication-competent disease, we used the pNL4-3 plasmid (72) and the pNL-vifS plasmid, EACC which harbors the entire gene of the simian immunodeficiency disease SIVmac239 in place of the NL4-3 gene and which was previously termed pNL-SVR (36). Numerous CA mutations were launched into these clones using standard cloning methods as explained previously (57). The DNA plasmid encoding the vesicular stomatitis disease G glycoprotein (VSV-G) (pMD2G) was explained previously (73). HIV-Gag-iGFPEnv and psPAX2 were used as explained by Mamede et al. (12), and the CA sequences of both plasmids were mutated: RGDA/Q112D, RGDA/Q112D+Q4R, and RGDA/Q112D+G94D/G116R. We verified all PCR-amplified regions of the plasmids by Sanger sequencing. To pseudotype the virions that were utilized for live-cell imaging, we used pCMV-VSV-G as previously explained (12, 14). ptdTomato-Vpr experienced the GFP sequence swapped from pGFP-Vpr and was previously described (74,.
Categories